LivaNova reports Q1 adjusted EPS 43c, consensus 39c

Reports Q1 revenue $263.4M, consensus $243.42M. "During the Q1, LivaNova delivered solid revenue growth," said Kozy. "Additionally, the Company achieved important product and clinical milestones, including U.S. FDA 510 clearance for Essenz and randomization of the 500th unipolar patient in the RECOVER clinical study. We look forward to building on this progress. I am engaging with our experienced executive leadership team as we maintain focus on executing on our core growth drivers, delivering on our clinical and product pipeline opportunities, and generating cash."